Last reviewed · How we verify
Polyclonal Regulatory T Cells
At a glance
| Generic name | Polyclonal Regulatory T Cells |
|---|---|
| Also known as | Polyclonal Tregs, polyTregs |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Foot fracture
- Gout
- Thrombophlebitis superficial
- Diarrhoea
- Nausea
- Urinary tract infection
- Contusion
- Hypercalcaemia
- Major depression
- Haemoptysis
- Swelling face
- Hypertension
Key clinical trials
- Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases (PHASE1)
- cePolyTregs in Islet Transplantation (PHASE1)
- Treg Therapy in Subclinical Inflammation in Kidney Transplantation (PHASE1, PHASE2)
- PolyTreg Immunotherapy in Islet Transplantation (PHASE1)
- Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus (PHASE1)
- Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS) (PHASE1)
- T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (PHASE1)
- Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |